-
公开(公告)号：US20130028902A1
公开(公告)日：2013-01-31
申请号：US13574196
申请日：2011-01-19
申请人： Gerard Karsenty , Patricia F. Ducy
发明人： Gerard Karsenty , Patricia F. Ducy
IPC分类号： A61K38/22 , A61P15/10 , G01N33/566 , A61K39/395 , A61K31/713 , A61P15/16 , A61P15/08 , A61K31/366
CPC分类号： A61K38/39
摘要： Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-IB signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes.
摘要翻译： 提供了用于治疗，预防或诊断与男性哺乳动物，优选人类繁殖相关的疾病的方法和组合物。 所述方法通常涉及OST-PTP信号通路的调节或涉及γ-羧化酶和骨钙素的PTP-IB信号传导途径的调节。 通过该方法治疗的疾病包括但不限于男性不育症，精子数量低，精子活力受损，精子活力受损，睾丸激素水平降低，性欲降低，勃起功能障碍，睾丸发育不全，睾丸过度凋亡。
-
公开(公告)号：US20110152220A1
公开(公告)日：2011-06-23
申请号：US12935651
申请日：2009-03-30
IPC分类号： A61K31/663 , A61K31/198 , A61K31/4375 , A61K31/513 , A61K31/36 , A61K31/472 , C07C229/36 , C07D455/03 , C07D317/60 , C07D217/20 , C07D211/34 , G01N33/53 , C07D221/18 , A61P19/10 , A61P35/04 , A61P19/08 , G01N27/26
CPC分类号： A61K31/505 , A61K31/357 , A61K31/513 , A61K45/06 , G01N33/942 , G01N2800/108 , G01N2800/50 , A61K2300/00
摘要： The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译： 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或减少骨质量。 在优选的实施方案中，已知患者具有或具有低骨量疾病如骨质疏松症的风险，并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
3.发明申请UNDERCARBOXYLATED/UNCARBOXYLATED OSTEOCALCIN INCREASES BETA-CELL PROLIFERATION, INSULIN SECRETION, INSULIN SENSITIVITY, GLUCOSE TOLERANCE AND DECREASES FAT MASS 审中-公开底物/非羧甲基纤维素增加蛋白质增殖，胰岛素分泌，胰岛素敏感性，葡萄糖耐量和降解脂肪公开(公告)号：US20100190697A1
公开(公告)日：2010-07-29
申请号：US12441045
申请日：2007-09-13
申请人： Gerard Karsenty , Patricia F. Ducy
发明人： Gerard Karsenty , Patricia F. Ducy
CPC分类号： G01N33/54306 , A61K38/16 , A61K38/39 , A61K47/60 , G01N33/5008 , G01N33/502 , G01N33/5023 , G01N33/5038 , G01N33/5088 , G01N2333/78 , G01N2333/916 , G01N2333/988
摘要： The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.
摘要翻译： 本发明涉及用于治疗和诊断与能量代谢有关的障碍的方法和组合物以及涉及γ-羧化酶，骨钙素和脂连蛋白的OST-PTP信号传导途径。 这些疾病包括但不限于代谢综合征，葡萄糖不耐受，1型和2型糖尿病，动脉粥样硬化和肥胖症。
-
公开(公告)号：US20150111908A1
公开(公告)日：2015-04-23
申请号：US14282177
申请日：2014-05-20
申请人： Gerard Karsenty , Patricia F. Ducy , Yuli Xie , Donald Landry , Vijay Yadav
发明人： Gerard Karsenty , Patricia F. Ducy , Yuli Xie , Donald Landry , Vijay Yadav
IPC分类号： A61K31/505
CPC分类号： A61K31/505 , A61K31/357 , A61K31/513 , A61K45/06 , G01N33/942 , G01N2800/108 , G01N2800/50 , A61K2300/00
摘要： The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译： 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或减少骨质量。 在优选的实施方案中，已知患者具有或具有低骨量疾病如骨质疏松症的风险，并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
公开(公告)号：US08759364B2
公开(公告)日：2014-06-24
申请号：US12935651
申请日：2009-03-30
IPC分类号： A61K31/505
CPC分类号： A61K31/505 , A61K31/357 , A61K31/513 , A61K45/06 , G01N33/942 , G01N2800/108 , G01N2800/50 , A61K2300/00
摘要： The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译： 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或减少骨质量。 在优选的实施方案中，已知患者具有或具有低骨量疾病如骨质疏松症的风险，并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
公开(公告)号：US20110281899A1
公开(公告)日：2011-11-17
申请号：US13128987
申请日：2009-11-13
IPC分类号： A61K31/513 , C07D409/12 , A61P19/08 , C07D403/12 , C07D413/12 , C07D417/12 , C07D401/12 , C07D405/12
CPC分类号： C07D239/47
摘要： The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译： 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或减少骨质量。 在优选的实施方案中，已知患者具有或具有低骨量疾病如骨质疏松症的风险，并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
7.发明授权Methods for identifying or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decrease fat mass 有权用于鉴定或测定增加β细胞增殖，胰岛素分泌，胰岛素敏感性，葡萄糖耐量和减少脂肪量的试剂的方法公开(公告)号：US09518976B2
公开(公告)日：2016-12-13
申请号：US12441060
申请日：2007-09-13
申请人： Gerard Karsenty , Patricia F. Ducy
发明人： Gerard Karsenty , Patricia F. Ducy
CPC分类号： G01N33/54306 , A61K38/16 , A61K38/39 , A61K47/60 , G01N33/5008 , G01N33/502 , G01N33/5023 , G01N33/5038 , G01N33/5088 , G01N2333/78 , G01N2333/916 , G01N2333/988
摘要： The present invention is directed to cell-based and non-cell based methods of drug screening to identify agents, or assay agents, that reduce OST-PTP or gamma-carboxylase activity or expression, or increase the level of undercarboxylated osteocalcin or adiponectin activity or expression. Such agents find use in treating or preventing a disorder related to the OST-PTP signaling pathway. Such disorders include, metabolic syndrome, glucose intolerance, type 1 or type 2 diabetes, atherosclerosis, or obesity. Such agents may be used to treat disorders characterized by decreased insulin production, deceased insulin sensitivity, and decreased glucose tolerance or increased fat mass.
摘要翻译： 本发明涉及基于细胞和非细胞的药物筛选方法，以鉴定减少OST-PTP或γ-羧化酶活性或表达或增加未羧化骨钙素或脂联素活性水平的试剂或测定试剂，或 表达。 这些药物可用于治疗或预防与OST-PTP信号通路相关的病症。 这些疾病包括代谢综合征，葡萄糖不耐受，1型或2型糖尿病，动脉粥样硬化或肥胖症。 这些药物可用于治疗以胰岛素产生减少，胰岛素敏感性降低，葡萄糖耐量降低或脂肪量增加为特征的疾病。
-
公开(公告)号：US08883739B2
公开(公告)日：2014-11-11
申请号：US13574196
申请日：2011-01-19
申请人： Gerard Karsenty , Patricia F. Ducy
发明人： Gerard Karsenty , Patricia F. Ducy
CPC分类号： A61K38/39
摘要： Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-IB signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes.
摘要翻译： 提供了用于治疗，预防或诊断与男性哺乳动物，优选人类繁殖相关的疾病的方法和组合物。 所述方法通常涉及OST-PTP信号通路的调节或涉及γ-羧化酶和骨钙素的PTP-IB信号传导途径的调节。 通过该方法治疗的疾病包括但不限于男性不育症，精子数量低，精子活力受损，精子活力受损，睾丸激素水平降低，性欲降低，勃起功能障碍，睾丸发育不全，睾丸过度凋亡。
-
公开(公告)号：US08614222B2
公开(公告)日：2013-12-24
申请号：US13128987
申请日：2009-11-13
IPC分类号： A61K31/505 , C07D239/47
CPC分类号： C07D239/47
摘要： The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译： 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂，以分别增加或减少骨质量。 在优选的实施方案中，已知患者具有或具有低骨量疾病如骨质疏松症的风险，并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
10.发明申请METHODS FOR IDENTIFYING OR ASSAYING FOR AGENTS THAT INCREASE BETA-CELL PROLIFERATION, INSULIN SECRETION, INSULIN SENSITIVITY, GLUCOSE TOLERANCE AND DECREASE FAT MASS 有权用于鉴定或测定增加细胞增殖，胰岛素分泌，胰岛素敏感性，葡萄糖耐量和降解脂肪的代谢物的方法公开(公告)号：US20100048409A1
公开(公告)日：2010-02-25
申请号：US12441060
申请日：2007-09-13
申请人： Gerard Karsenty , Patricia F. Ducy
发明人： Gerard Karsenty , Patricia F. Ducy
CPC分类号： G01N33/54306 , A61K38/16 , A61K38/39 , A61K47/60 , G01N33/5008 , G01N33/502 , G01N33/5023 , G01N33/5038 , G01N33/5088 , G01N2333/78 , G01N2333/916 , G01N2333/988
摘要： The present invention is directed to cell-based and non-cell based methods of drug screening to identify agents, or assay agents, that reduce OST-PTP or gamma-carboxylase activity or expression, or increase the level of undercarboxylated osteocalcin or adiponectin activity or expression. Such agents find use in treating or preventing a disorder related to the OST-PTP signaling pathway. Such disorders include, metabolic syndrome, glucose intolerance, type 1 or type 2 diabetes, atherosclerosis, or obesity. Such agents may be used to treat disorders characterized by decreased insulin production, deceased insulin sensitivity, and decreased glucose tolerance or increased fat mass.
摘要翻译： 本发明涉及基于细胞和非细胞的药物筛选方法，以鉴定减少OST-PTP或γ-羧化酶活性或表达或增加未羧化骨钙素或脂联素活性水平的试剂或测定试剂，或 表达。 这些药物可用于治疗或预防与OST-PTP信号通路相关的病症。 这些疾病包括代谢综合征，葡萄糖不耐受，1型或2型糖尿病，动脉粥样硬化或肥胖症。 这些药物可用于治疗以胰岛素产生减少，胰岛素敏感性降低，葡萄糖耐量降低或脂肪量增加为特征的疾病。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
